Erectile Dysfunction
Conditions
Keywords
Erectile dysfunction,, Phosphodiesterase Inhibitors
Brief summary
This investigation targets either the patients of 18 years-old or older and under 65 years-old with organic or mixed erectile dysfunction (ED) who cannot obtain sufficient efficacy by dose 10mg of Levitra, and the target patients dose is increased to Levitra 20mg. This investigation will be limited to the patients whose tolerability of Levitra 10mg is judged to be no problem.
Interventions
DRUGVardenafil, (Levitra, BAY38-9456)
Patients under daily life treatment receiving Levitra according to local drug information.
Sponsors
Bayer
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
MALE
Age
18 Years to 64 Years
Healthy volunteers
No
Inclusion criteria
* This investigation targets either the patients of 18 years-old or older and under 65 years-old with organic or mixed erectile dysfunction who cannot obtain sufficient efficacy by dose 10mg of Levitra, and the target patients dose is increased to Levitra 20mg. This investigation will be limited to the patients whose tolerability of Levitra 10mg is judged to be no problem.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy of patients with LEVITRA treatment | After 6 months |
Secondary
| Measure | Time frame |
|---|---|
| LEVITRA treatment improved the patient's erection | After 6 months |
| LEVITRA improved the patient's erection after Minimum and Maximum Intervals between LEVITRA intake and the start of intercourse | After 6 months |
| Reporting a second successful intercourse within 24 hours of dosing | After 6 months |
| Patients prefer LEVITRA over last Erectile Dysfunction treatment | After 6 months |
| Tolerability of patients with LEVITRA treatment | After 6 months |
Countries
Japan
Outcome results
None listed